Display options
Cite
El-Garem H, Ammer A, Shehab H, et al. Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma. World J Hepatol. 2014;6(11):818-24doi: 10.4254/wjh.v6.i11.818.
El-Garem, H., Ammer, A., Shehab, H., Shaker, O., Anwer, M., El-Akel, W., & Omar, H. (2014). Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma. World journal of hepatology, 6(11), 818-24. https://doi.org/10.4254/wjh.v6.i11.818
El-Garem, Hassan, et al. "Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma." World journal of hepatology vol. 6,11 (2014): 818-24. doi: https://doi.org/10.4254/wjh.v6.i11.818
El-Garem H, Ammer A, Shehab H, Shaker O, Anwer M, El-Akel W, Omar H. Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma. World J Hepatol. 2014 Nov 27;6(11):818-24. doi: 10.4254/wjh.v6.i11.818. PMID: 25429320; PMCID: PMC4243156.
Copy Download .nbib Format: NLM
Share it on

World J Hepatol. 2014 Nov 27;6(11):818-24. doi: 10.4254/wjh.v6.i11.818.

Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma.

World journal of hepatology

Hassan El-Garem, Ayman Ammer, Hany Shehab, Olfat Shaker, Mohammed Anwer, Wafaa El-Akel, Heba Omar

Affiliations

  1. Hassan El-Garem, Ayman Ammer, Hany Shehab, Mohammed Anwar, Wafaa El-Akel, Heba Omar, Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Cairo 12613, Egypt.

PMID: 25429320 PMCID: PMC4243156 DOI: 10.4254/wjh.v6.i11.818

Abstract

AIM: To explore the potential usefulness of serum miR-122 and miR-221 as non-invasive diagnostic markers of hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC).

METHODS: This prospective study was conducted on 90 adult patients of both sex with HCV-related chronic liver disease and chronic hepatitis C related HCC. In addition to the 10 healthy control individuals, patients were stratified into; interferon-naïve chronic hepatitis C (CH) (n = 30), post-hepatitis C compensated cirrhosis (LC) (n = 30) and treatment-naïve HCC (n = 30). All patients and controls underwent full clinical assessment and laboratory investigations in addition to the evaluation of the level of serum miRNA expression by RT-PCR.

RESULTS: There was a significant fold change in serum miRNA expression in the different patient groups when compared to normal controls; miR-122 showed significant fold increasing in both CH and HCC and significant fold decrease in LC. On the other hand, miR-221 showed significant fold elevation in both CH and LC groups and significant fold decrease in HCC group (P = 0.01). Comparing fold changes in miRNAs in HCC group vs non HCC group (CH and Cirrhosis), there was non-significant fold elevation in miR-122 (P = 0.21) and significant fold decreasing in miR-221 in HCC vs non-HCC (P = 0.03). ROC curve analysis for miR-221 yielded 87% sensitivity and 40% specificity for the differentiation of HCC patients from non-HCC at a cutoff 1.82.

CONCLUSION: Serum miR-221 has a strong potential to serve as one of the novel non-invasive biomarkers of HCC.

Keywords: Hepatocellular carcinoma; MiRNA; Serum

References

  1. Am J Pathol. 2008 Sep;173(3):856-64 - PubMed
  2. Gastroenterology. 2009 Jul;137(1):110-8 - PubMed
  3. Gastroenterology. 2004 Nov;127(5 Suppl 1):S113-9 - PubMed
  4. Ethn Dis. 2005 Winter;15(1 Suppl 1):S1-3-4 - PubMed
  5. Annu Rev Cell Dev Biol. 2007;23:175-205 - PubMed
  6. Am J Gastroenterol. 1998 Jun;93(6):896-900 - PubMed
  7. Hepatol Int. 2008 Mar;2(1):17-30 - PubMed
  8. Liver Int. 2003 Oct;23 (5):329-37 - PubMed
  9. Hepatology. 2008 Apr;47(4):1223-32 - PubMed
  10. J Biol Chem. 2008 May 9;283(19):13205-15 - PubMed
  11. Hepatol Res. 2009 Aug;39(8):786-94 - PubMed
  12. Hepatology. 2008 Jun;47(6):1955-63 - PubMed
  13. J Hepatol. 2012 Jun;56(6):1371-83 - PubMed
  14. Lancet. 2003 Dec 6;362(9399):1907-17 - PubMed
  15. Cancer. 2000 Feb 1;88(3):544-9 - PubMed
  16. Gastroenterology. 2007 Aug;133(2):647-58 - PubMed
  17. Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 - PubMed
  18. Hepatology. 2003 Mar;37(3):520-7 - PubMed
  19. Eur J Cancer. 2013 Nov;49(16):3442-9 - PubMed
  20. J Clin Gastroenterol. 2002 Nov-Dec;35(5 Suppl 2):S72-8 - PubMed
  21. Gastroenterology. 1984 Jun;86(6):1404-9 - PubMed
  22. Mol Carcinog. 2011 Feb;50(2):136-42 - PubMed
  23. Hepatology. 2005 Nov;42(5):1208-36 - PubMed
  24. J Hepatol. 2013 Feb;58(2):234-9 - PubMed
  25. BMC Cancer. 2013 Jan 16;13:21 - PubMed

Publication Types